Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ABBV

Abbvie Inc

Nov 12 • 04:00PM ET

233.23

+8.06 3.58 %

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: JNJ PFE MRK LLY BMY GILD AMGN REGN VRTX BIIB

| Held by: VTI VOO IVV SPY VTV SCHD XLV VIG VYM IWF

Scroll to Statements

Index	S&P 500	P/E	175.98	EPS (ttm)	1.33	Insider Own	0.13%	Shs Outstand	1.77B	Perf Week	7.59%
Market Cap	412.21B	Forward P/E	16.31	EPS next Y	14.30	Insider Trans	-2.37%	Shs Float	1.77B	Perf Month	1.79%
Enterprise Value	475.32B	PEG	10.89	EPS next Q	3.35	Inst Own	74.28%	Short Float	1.07%	Perf Quarter	13.95%
Income	2.35B	P/S	6.91	EPS this Y	5.07%	Inst Trans	0.05%	Short Ratio	3.46	Perf Half Y	31.44%
Sales	59.64B	P/B	-	EPS next Y	34.45%	ROA	1.69%	Short Interest	18.89M	Perf YTD	31.25%
Book/sh	-1.49	P/C	72.69	EPS next 5Y	16.16%	ROE	138.53%	52W High	244.81 -4.73%	Perf Year	16.91%
Cash/sh	3.21	P/FCF	20.94	EPS past 3/5Y	-28.18% -14.67%	ROIC	3.89%	52W Low	163.81 42.38%	Perf 3Y	57.48%
Dividend Est.	6.51 (2.79%)	EV/EBITDA	17.37	Sales past 3/5Y	0.08% 11.11%	Gross Margin	69.68%	Volatility	2.44% 1.92%	Perf 5Y	148.94%
Dividend TTM	6.56 (2.81%)	EV/Sales	7.97	EPS Y/Y TTM	-53.78%	Oper. Margin	31.95%	ATR (14)	5.02	Perf 10Y	265.56%
Dividend Ex-Date	Jan 16, 2026	Quick Ratio	0.60	Sales Y/Y TTM	7.40%	Profit Margin	3.94%	RSI (14)	61.97	Recom	1.85
Dividend Gr. 3/5Y	5.81% 7.46%	Current Ratio	0.72	EPS Q/Q	-88.66%	SMA20	3.85%	Beta	0.35	Target Price	246.74
Payout	263.15%	Debt/Eq	-	Sales Q/Q	9.10%	SMA50	4.10%	Rel Volume	1.53	Prev Close	225.17
Employees	55000	LT Debt/Eq	-	Earnings	Oct 31 BMO	SMA200	15.78%	Avg Volume	5.46M	Price	233.23
IPO	Dec 10, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	5.34% 1.22%	Trades		Volume	8,337,853	Change	3.58%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-04-25	Downgrade	DZ Bank	Buy → Hold	$237
Oct-14-25	Downgrade	Erste Group	Buy → Hold
Oct-01-25	Downgrade	HSBC Securities	Buy → Hold
Sep-17-25	Upgrade	Berenberg	Hold → Buy	$270
Aug-12-25	Resumed	Piper Sandler	Overweight	$231
Aug-07-25	Upgrade	Daiwa Securities	Neutral → Outperform	$214
May-14-25	Downgrade	Citigroup	Buy → Neutral	$205
Apr-22-25	Initiated	Cantor Fitzgerald	Overweight	$210
Dec-10-24	Resumed	BofA Securities	Neutral	$191
Dec-05-24	Downgrade	Daiwa Securities	Outperform → Neutral	$180
Nov-22-24	Upgrade	Leerink Partners	Market Perform → Outperform	$206
Nov-15-24	Initiated	Wolfe Research	Outperform	$205
Nov-04-24	Upgrade	Argus	Hold → Buy
Oct-17-24	Initiated	Bernstein	Mkt Perform	$203
Jun-05-24	Upgrade	HSBC Securities	Hold → Buy	$185
May-17-24	Initiated	Cantor Fitzgerald	Overweight	$200
Jan-29-24	Upgrade	William Blair	Mkt Perform → Outperform
Dec-18-23	Downgrade	HSBC Securities	Buy → Hold
Dec-11-23	Upgrade	Goldman	Neutral → Buy
Nov-09-23	Initiated	Deutsche Bank	Hold	$150

Show Previous Ratings

Nov-12-25 04:30PM	BeOne, IBD Stock Of The Day, Breaks Out As It Takes On Cancer Giants J&J, AbbVie (Investor's Business Daily)
12:55PM	IBD Stock Of The Day BeOne Breaks Out As It Takes On Cancer Giants J&J, AbbVie (Investor's Business Daily)
11:51AM	How Much Did Skyrizi and Rinvoq Drive AbbVie's Q3 Performance? (Zacks)
09:18AM	AbbVie (ABBV) Surged Following Strong Results and Increased Guidance (Insider Monkey)
08:30AM	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence (PR Newswire)
10:50AM	Loading…
Nov-11-25 10:50AM	Three Healthcare Buys That Wall Street Loves (Motley Fool)
09:56AM	IRWD Beats on Q3 Earnings & Revenues, Raises 2025 View, Stock Soars (Zacks)
08:49AM	5 Top Stocks to Buy in November (Motley Fool)
Nov-10-25 07:47AM	Does Trump's MFN Policy Put Pharma ETFs in the Crosshairs? (Zacks)
Nov-09-25 11:05AM	What Is Considered a Good Stock Dividend? 3 Healthcare Stocks That Fit the Bill. (Motley Fool)
04:21AM	Got $5,000? These Are 3 of the Cheapest Growth Stocks to Buy Right Now (Motley Fool)
Nov-08-25 12:36AM	Piper Sandler Raises AbbVie (ABBV) Price Target to $289, Maintains Overweight Rating (Insider Monkey)
Nov-07-25 12:32AM	The Top 5 Analyst Questions From AbbVie's Q3 Earnings Call (StockStory)
Nov-06-25 08:45AM	3 Dividend Stocks Down 11%, 29%, and 41% to Buy in November (Motley Fool)
07:35AM	Former blockbuster Linzess grows label with paediatric IBS-C approval (Pharmaceutical Technology)
06:30AM	Loading…
06:30AM	Lower interest rates could boost these stocks & sectors (Yahoo Finance Video)
Nov-05-25 11:11PM	Jim Cramer Says "I Found the AbbVie Call Particularly Jarring" (Insider Monkey)
07:30PM	AbbVie Just Raised Its Dividend by 5.5%. Should You Buy ABBV Stock Here? (Barchart)
04:49PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
09:00AM	Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know (Zacks)
Nov-04-25 09:11AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: Apple, AbbVie, Broadcom, CyberArk, Palantir Technologies and More (24/7 Wall St.)
05:15AM	2 Healthcare Stocks for Individual Investors With a 10-Year Time Horizon (Motley Fool)
Nov-03-25 02:41PM	Do Wall Street Analysts Like AbbVie Stock? (Barchart)
09:35AM	ABBV Q3 Deep Dive: Immunology Growth and Pipeline Expansion Offset Margin Pressure (StockStory)
09:19AM	Here's What Drove Baron Health Care Fund to Add AbbVie (ABBV) to Its Portfolio (Insider Monkey)
08:21AM	Analyst on AbbVie (ABBV): 'Stay Long' (Insider Monkey)
07:30AM	My Favorite Dividend King to Buy in November (Motley Fool)
Nov-02-25 09:21PM	Analyst Report: AbbVie Inc. (Morningstar Research)
09:15AM	2 Magnificent Dividend Stocks to Buy and Hold Forever (Motley Fool)
08:14AM	2 Top ETFs I Can't Wait to Buy More of in My Retirement Account This November (Motley Fool)
12:35PM	Loading…
Nov-01-25 12:35PM	ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat (MarketBeat)
06:15AM	Why AbbVie Stock Flopped on Friday (Motley Fool)
Oct-31-25 04:06PM	AbbVie Beats Third-Quarter Forecasts As Immunology Kingpin Grows 47% (Investor's Business Daily)
03:04PM	AbbVie Inc (ABBV) Q3 2025 Earnings Call Highlights: Strong Financial Performance Amidst Humira ... (GuruFocus.com)
02:08PM	AbbVie raises full-year forecast, Newell Brands stock plunges (Yahoo Finance Video)
02:06PM	AbbVie Q3 Earnings & Sales Beat, 2025 EPS Outlook Raised (Zacks)
01:02PM	Why AbbVie (ABBV) Shares Are Falling Today (StockStory)
12:36PM	Health Care Roundup: Market Talk (The Wall Street Journal)
12:01PM	Dow Is Hovering Around Breakeven (Barrons.com)
11:08AM	Reddit, AbbVie, Western Digital: Earnings in focus (Yahoo Finance Video)
11:00AM	AbbVie (ABBV) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
10:51AM	Demographic Megatrend: Stocks Poised to Benefit From Global Aging (Zacks)
09:00AM	AbbVie (ABBV) Q3 Earnings and Revenues Surpass Estimates (Zacks)
08:42AM	AbbVie Lifts Profit Outlook as Sales Rise (The Wall Street Journal)
08:28AM	AbbVie lifts full-year profit outlook amid strong psoriasis drug demand (Investing.com)
08:20AM	AbbVie Beats Third-Quarter Estimates. There's More to the Drugmaker's Earnings. (Barrons.com)
08:11AM	AbbVie's (NYSE:ABBV) Q3 Sales Beat Estimates (StockStory)
07:58AM	AbbVie: Q3 Earnings Snapshot (Associated Press Finance)
07:49AM	AbbVie Reports Third-Quarter 2025 Financial Results (PR Newswire)
04:34AM	Exxon Mobil, Berkshire Earnings: Still to Come This Week (The Wall Street Journal)
Oct-30-25 07:00PM	Exxon & Chevron earnings, Fed, YouTube-Disney: What to Watch (Yahoo Finance Video)
08:32AM	AbbVie posts another win for Rinvoq in Phase III vitiligo trials (Clinical Trials Arena)
05:47AM	Amazon, Apple Earnings, ECB Rate Decision: Still to Come This Week (The Wall Street Journal)
Oct-29-25 11:01PM	AbbVie (ABBV) Reports Earnings Tomorrow: What To Expect (StockStory)
05:00PM	The One & Only BOTOX Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year (PR Newswire)
03:08PM	Trump Administration Eases Approval Process for Biosimilar Drugs (Barrons.com)
08:11AM	AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ) in Adults and Adolescents with Vitiligo (PR Newswire)
Oct-28-25 11:35AM	3 Cancer-Focused Stocks Showing Strong Pipeline Progress (Zacks)
10:00AM	Earnings Preview: Pfizer (PFE) Q3 Earnings Expected to Decline (Zacks)
09:00AM	Allergan Aesthetics and Girls Inc., in Partnership with SkinSpirit, Inspire Future Women Leaders in STEM (PR Newswire)
08:48AM	Should You Buy AbbVie Stock Ahead of Q3 Earnings Report? (Zacks)
06:26AM	Billionaire Israel "Izzy" Englander Has Loaded Up on This Dividend King. Should You? (Motley Fool)
Oct-27-25 11:05AM	What's in Store for These 5 Pharma Bigwigs This Earnings Season? (Zacks)
Oct-26-25 11:21AM	Prediction: These Dividend Stocks Could Outperform Growth Stocks in the Next Decade (Motley Fool)
Oct-24-25 07:45PM	AI Chatbots Were Told to Trade Crypto. The Returns Were Ugly. (Barrons.com)
07:00PM	Big Tech earnings, Fed meeting, Trump & Xi meet: What to Watch (Yahoo Finance Video)
10:00AM	Analysts Estimate AbbVie (ABBV) to Report a Decline in Earnings: What to Look Out for (Zacks)
09:30AM	Wall Street Analysts Think AbbVie (ABBV) Is a Good Investment: Is It? (Zacks)
Oct-23-25 11:13AM	3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years (MarketBeat)
Oct-22-25 07:00PM	AbbVie: Navigating Challenges and Seizing Opportunities in the Pharma Sector (Motley Fool)
05:45PM	AbbVie (ABBV) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks)
03:44PM	Analyst Says He Likes AbbVie (ABBV) Amid 'Attractive' Valuation (Insider Monkey)
02:31PM	AbbVie Inc. (ABBV): A Bull Case Theory (Insider Monkey)
10:29AM	AbbVie Up More Than 30% in 6 Months: How to Play the Stock (Zacks)
09:00AM	Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock (Zacks)
Oct-21-25 07:57PM	This 3 Stocks Portfolio Provides Monthly Income (Zacks)
04:17PM	Top Stock Reports for Apple, Meta Platforms & JPMorgan (Zacks)
03:19PM	Final Trades: Abbvie, Qualcomm, Aptiv, and Palo Alto Networks (CNBC TV)
12:07PM	AbbVie's Rinvoq Beats Humira in Key Arthritis Trial (GuruFocus.com)
08:00AM	The Confidence Project by BOTOX Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients (PR Newswire)
Oct-20-25 10:10AM	Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings (Zacks)
08:00AM	RINVOQ (upadacitinib) Demonstrated Superiority Versus HUMIRA (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor (PR Newswire)
Oct-18-25 09:05AM	AbbVie completes acquisition of Gilgamesh Pharmaceuticals bretisilocin (TipRanks)
Oct-17-25 09:00AM	AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin (PR Newswire)
Oct-16-25 06:45AM	Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever. (Motley Fool)
01:49AM	Cantor Fitzgerald Reaffirms Overweight Rating on AbbVie (ABBV) (Insider Monkey)
Oct-15-25 05:45PM	AbbVie (ABBV) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
09:00AM	3 Top Dividend Growth Stocks to Buy Right Now (Motley Fool)
08:30AM	Enveric Biosciences hires Fish & Richardson to defend patent tied to AbbVie deal (Investing.com)
Oct-14-25 11:09AM	Can Rinvoq and Skyrizi Sales Drive Another Strong Quarter for AbbVie? (Zacks)
Oct-13-25 01:49PM	Final Trades: Abbvie, Amazon, Datadog and Sixth Street Specialty Lending (CNBC TV)
01:40PM	AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve (Zacks)
10:57AM	U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ (upadacitinib) for the Treatment of Inflammatory Bowel Disease (PR Newswire)
09:53AM	2 Dividend Stocks to Double Up on Right Now (Motley Fool)
07:15AM	AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors (PR Newswire)
Oct-10-25 09:00AM	Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? (Zacks)
02:59AM	What to Expect From AbbVie's Q3 2025 Earnings Report (Barchart)
Oct-09-25 10:14AM	AbbVie vs. Eli Lilly: Which Large Drugmaker Has the Edge in 2025? (Zacks)
08:00AM	SkinMedica Debuts Reimagined Packaging and Unveils New HA5 Hydra Collagen Water Burst Moisturizer (PR Newswire)
02:05AM	How pharma giant AbbVie holds leaders accountable for culture (Fortune)

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Richard A. Gonzalez	Former Director	Aug 22 '25	Proposed Sale	210.84	62,755	13,231,264		Aug 22 06:02 PM
Richard A. Gonzalez	Former Director	Aug 21 '25	Proposed Sale	211.04	90,000	18,993,948		Aug 21 06:04 PM
SALEKI-GERHARDT AZITA	EVP, CHIEF OPERATIONS OFFICER	Aug 12 '25	Option Exercise	54.86	42,370	2,324,418	219,662	Aug 14 05:00 PM
SALEKI-GERHARDT AZITA	EVP, CHIEF OPERATIONS OFFICER	Aug 12 '25	Sale	198.42	42,370	8,407,055	177,292	Aug 14 05:00 PM
AZITA SALEKI-GERHARDT	Officer	Aug 12 '25	Proposed Sale	198.42	42,370	8,407,068		Aug 12 07:22 PM
Richard A. Gonzalez	Former Director	Aug 01 '25	Proposed Sale	195.83	61,500	12,043,268		Aug 08 05:03 PM
Donoghoe Nicholas	EVP, CHIEF BUS/STRAT OFFICER	Aug 05 '25	Sale	198.51	13,295	2,639,253	58,247	Aug 07 05:00 PM
NICHOLAS DONOGHOE	Officer	Aug 05 '25	Proposed Sale	198.51	13,299	2,639,966		Aug 05 04:40 PM
Stewart Jeffrey Ryan	EVP, CHIEF COMMERCIAL OFFICER	Mar 31 '25	Option Exercise	79.02	25,700	2,030,814	112,066	Apr 02 05:00 PM
Stewart Jeffrey Ryan	EVP, CHIEF COMMERCIAL OFFICER	Mar 31 '25	Sale	210.08	58,832	12,359,504	53,234	Apr 02 05:00 PM
Stewart Jeffrey Ryan	Officer	Mar 31 '25	Proposed Sale	210.09	58,832	12,359,897		Mar 31 05:30 PM
Reents Scott T	EVP, CHIEF FINANCIAL OFFICER	Mar 14 '25	Sale	212.34	17,644	3,746,527	11,577	Mar 18 05:00 PM
Reents Scott T	Officer	Mar 14 '25	Proposed Sale	212.35	17,644	3,746,628		Mar 14 04:34 PM
GONZALEZ RICHARD A	Director	Feb 28 '25	Sale	205.11	92,460	18,964,471	395,097	Mar 04 05:00 PM
GONZALEZ RICHARD A	Director	Mar 03 '25	Sale	210.53	6,168	1,298,549	388,929	Mar 04 05:00 PM
Siatis Perry C	EVP, GC AND SECRETARY	Mar 03 '25	Option Exercise	159.88	18,008	2,879,040	22,627	Mar 04 05:00 PM
Siatis Perry C	EVP, GC AND SECRETARY	Mar 03 '25	Sale	210.00	18,008	3,781,680	4,619	Mar 04 05:00 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 28 '25	Sale	206.30	9,892	2,040,722	4,619	Mar 04 05:00 PM
RICHMOND TIMOTHY J.	EVP, CHIEF HR OFFICER	Mar 03 '25	Sale	210.45	21,250	4,472,039	6,130	Mar 04 05:00 PM
GONZALEZ RICHARD A	Officer	Mar 03 '25	Proposed Sale	210.53	6,168	1,298,550		Mar 03 05:57 PM
PERRY C SIATIS	Officer	Mar 03 '25	Proposed Sale	210.00	18,008	3,781,680		Mar 03 04:28 PM
TIMOTHY RICHMOND	Officer	Mar 03 '25	Proposed Sale	210.46	21,250	4,472,184		Mar 03 04:08 PM
GONZALEZ RICHARD A	Officer	Feb 28 '25	Proposed Sale	205.11	92,460	18,964,882		Feb 28 05:37 PM
Buckbee Kevin K	SVP, CONTROLLER	Feb 26 '25	Option Exercise	98.48	16,260	1,601,313	28,906	Feb 28 05:00 PM
Buckbee Kevin K	SVP, CONTROLLER	Feb 26 '25	Sale	203.41	18,944	3,853,372	11,496	Feb 28 05:00 PM
RICHMOND TIMOTHY J.	EVP, CHIEF HR OFFICER	Feb 26 '25	Option Exercise	114.36	22,210	2,539,936	66,494	Feb 28 05:00 PM
RICHMOND TIMOTHY J.	EVP, CHIEF HR OFFICER	Feb 26 '25	Sale	202.90	29,917	6,070,036	44,284	Feb 28 05:00 PM
PERRY C SIATIS	Officer	Feb 28 '25	Proposed Sale	206.31	9,892	2,040,790		Feb 28 04:12 PM
Buckbee Kevin K	Officer	Feb 26 '25	Proposed Sale	203.41	18,944	3,853,398		Feb 26 05:47 PM
TIMOTHY RICHMOND	Officer	Feb 26 '25	Proposed Sale	202.90	29,917	6,070,176		Feb 26 04:04 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 20 '25	Sale	197.90	5,778	1,143,453	22,381	Feb 24 05:00 PM
PERRY C SIATIS	Officer	Feb 20 '25	Proposed Sale	197.90	5,778	1,143,492		Feb 20 04:10 PM
Buckbee Kevin K	SVP, CONTROLLER	Dec 16 '24	Option Exercise	93.50	1,800	168,300	8,783	Dec 18 05:00 PM
Buckbee Kevin K	SVP, CONTROLLER	Dec 16 '24	Sale	172.24	1,800	310,032	6,983	Dec 18 05:00 PM
Buckbee Kevin K	Officer	Dec 16 '24	Proposed Sale	172.25	1,800	310,045		Dec 16 05:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABBV

Abbvie Inc

Upgrade your FINVIZ experience